Overview

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Status:
RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Phase:
PHASE2
Details
Lead Sponsor:
Climb Bio, Inc.